CorMedix Inc. to Announce Financial Results and Corporate Update
CorMedix Inc. (NASDAQ: CRMD), a leading biopharmaceutical company, is gearing up to report its financial performance for the third quarter of 2025. This announcement is set to take place before the market opens on November 12, 2025. In addition to the financial results, CorMedix will conduct a corporate update conference call at 8:30 am Eastern Time, offering investors and stakeholders insights into the company’s latest developments.
Details of the Conference Call
The conference call on November 12 will provide a platform for the management team of CorMedix to discuss the financial outcomes and share valuable information regarding ongoing projects and strategic initiatives. Those interested in participating can join via:
- Domestic: 1-844-676-2922
- International: 1-412-634-6840
About CorMedix Inc.
CorMedix Inc. is dedicated to creating and commercializing therapeutic solutions targeting serious diseases and conditions. Their flagship product, DefenCath, is designed for preventing catheter-related bloodstream infections among adult patients who rely on hemodialysis through central venous catheters. Moreover, following the acquisition of Melinta Therapeutics LLC, CorMedix expanded its portfolio with several anti-infective medications such as:
- MINOCIN (minocycline)
- REZZAYO (rezafungin)
- VABOMERE (meropenem and vaborbactam)
- ORBACTIV (oritavancin)
- BAXDELA (delafloxacin)
- KIMYRSA (oritavancin)
- TOPROL-XL (metoprolol succinate)
Current Developments and Future Plans
As part of its commitment to innovation, CorMedix is conducting ongoing clinical trials to evaluate the efficacy of DefenCath within other patient demographics, including those receiving Total Parenteral Nutrition and pediatric patients. Furthermore, the company aims to develop DefenCath as a versatile catheter lock solution applicable to diverse medical scenarios.
Additionally, REZZAYO is currently endorsed for treating candidemia and invasive candidiasis in adults and is undergoing a Phase III clinical study aimed at preventing infections in adult patients undergoing allogeneic bone marrow transplants. The anticipated results from this pivotal Phase III study are expected to unfold in the second quarter of 2026, showcasing CorMedix's ongoing dedication to addressing critical medical needs.
Investor Relations and Further Information
For investors seeking more information about CorMedix and its initiatives, a variety of resources are available. The corporate website is an excellent starting point, providing extensive details on their products, research, and contact information. Interested parties can reach out to:
Investor Contact:
Dan Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
Frequently Asked Questions
When will CorMedix Inc. report its Q3 2025 financial results?
CorMedix Inc. is set to report its financial results for the third quarter on November 12, 2025.
What products does CorMedix focus on?
CorMedix focuses on developing therapeutic products for the prevention and treatment of severe medical conditions, including DefenCath and a range of anti-infectives acquired from Melinta Therapeutics.
How can investors participate in the conference call?
Investors can participate in the conference call by dialing 1-844-676-2922 for domestic calls or 1-412-634-6840 for international calls.
What is the significance of the Phase III study for REZZAYO?
The Phase III study for REZZAYO is crucial for determining its effectiveness in preventing infections in adult patients undergoing allogeneic bone marrow transplants, with results expected in the second quarter of 2026.
Who can I contact for more information about CorMedix?
For information regarding CorMedix, you can contact Dan Ferry, Managing Director at LifeSci Advisors, via email at daniel@lifesciadvisors.com or call (617) 430-7576.
